Intensity Therapeutics Q1 net loss $4.6M; cash $10.5M funds operations into Q1 2025

INTENSITY THERAPEUTICS, INC.

2024-Q1 EPS reported -$0.34

Net loss of $4.6M in Q1 2024 vs $1.3M in Q1 2023; R&D expenses rose to $2.8M from $0.8M, G&A to $1.9M from $0.5M.
Cash, cash equivalents and marketable debt securities totaled $10.5M as of Mar 31, 2024; expected to fund operations through Q1 2025.
Intends to initiate Phase 3 INVINCIBLE-3 Study in mid-2024: INT230-6 monotherapy vs SOC in soft tissue sarcoma, 333 patients, overall survival endpoint.
Intends to initiate Phase 2/3 INVINCIBLE-4 Study in mid-2024: INT230-6 + SOC in neoadjuvant triple negative breast cancer, endpoint pCR.
Over 30 sites screened for INVINCIBLE-3; contracts in process; Phase 3 clinical supplies released and shipped.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTENSITY THERAPEUTICS, INC. reported the three months ended March 31, 2024 results: net income Net loss was $4.6 million.

Period: the three months ended March 31, 2024
Net income: Net loss was $4.6 million
Result: reported results

Exact text from the filing

On May 9, 2024, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three months ended March 31, 2024.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

INTENSITY THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001567264-24-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.